| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 4, 2007
Accepted on July 24, 2007
Pediatric Endocrinology Department, Centre de Référence Maladies Endocriniennes de la Croissance and Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 690, Radiology and Biochemistry Department, Unit of Clinical Epidemiology INSERM CIE5, Assistance Publique-Hôpitaux de Paris, Robert Debré Hospital, Université Paris VII, Paris, France
* To whom correspondence should be addressed. E-mail: juliane.leger{at}rdb.aphp.fr.
Context: The unexpected observation of a normal GH peak in 22% of young adults with childhood-onset GHD and ectopic neurohypophysis has raised questions about the criteria defining GHD in young adults and whether patients with subsequent increases in GH secretion nonetheless have a subtle form of GH deficiency.
Objective: To determine the characteristics of patients with childhood-onset non acquired GHD who recover normal peak GH secretion when adult height has been achieved.
Design: Observational follow-up study.
Setting: University hospital-based study
Participants: Sixty-two patients with ectopic neurohypophysis (n=24), isolated hypoplastic anterior pituitary (n=14) or normal hypothalamic pituitary area (n=24) on MRI at the time of GHD diagnosis, underwent reevaluation of the GH-IGF-I axis at a mean age of 16.8±1.6 years.
Main outcome measures: Clinical and MRI findings, serum IGF-I and peak GH levels.
Results: On retesting, peak GH exceeded 10 µg/L in 31 patients (50%) — 6 (20%) patients with ectopic neurohypophysis, 10 (32%) patients with initially isolated hypoplastic anterior pituitary and 15 (48%) patients with normal MRI findings. Among these patients, serum IGF-I levels were significantly lower in patients with ectopic neurohypophysis than in those without structural abnormalities of the hypothalamic pituitary axis (n=25), but patients without structural abnormalities also had significantly lower serum IGF-I levels than control subjects, after controlling for age, sex and BMI (mean serum IGF-I levels of 374 ± 83 vs. 446 ± 108 µg/L,
coefficient = -72; p = 0.003).
Conclusions: The severity of the disease seems to have decreased over time in these patients, who may nonetheless present persistent pituitary failure. The natural history and clinical implications of these findings remain to be clarified. The possibility of a deterioration in the secretion of GH and other pituitary hormones later in life in a subset of these patients warrants the careful long-term follow-up of this population.
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |